Novartis Pharmaceuticals

This study is testing a one-time gene therapy called DFT383 in young children (ages 2-5) with nephropathic cystinosis, a rare and serious genetic disease that damages the kidneys and other organs. The main goals are to see if the treatment is safe and if it can reverse kidney dam…

This study is testing whether adding an investigational drug called iptacopan to standard lupus nephritis treatment helps patients' kidneys recover better. It will involve about 240 adults with active kidney inflammation from lupus. Researchers will compare different doses of ipt…

This study is testing the drug ruxolitinib in Chinese adults and adolescents (aged 12+) who have chronic graft-versus-host disease (cGvHD) that does not improve with standard steroid treatment. The goal is to see if ruxolitinib can help control the disease and reduce symptoms. Ab…

This study is testing whether an oral medication called iptacopan can help people with a rare kidney disease called idiopathic immune-complex-mediated membranoproliferative glomerulonephritis (IC-MPGN). About 106 adults and adolescents will take either iptacopan or a placebo pill…

This study is testing whether an oral medication called remibrutinib can safely reduce painful skin lesions in people with moderate-to-severe hidradenitis suppurativa (HS). About 555 participants aged 12 and older will take either one of two doses of the drug or a placebo pill fo…

This early-stage study is testing a single dose of an experimental cell therapy called YTB323 in about 28 adults with relapsing multiple sclerosis. The goal is to see if this treatment is safe and can help control the disease in patients whose current high-efficacy medications ar…

This study monitors the long-term safety of secukinumab, a medication for autoimmune and inflammatory conditions. It's for people who have already been taking secukinumab in a previous Novartis study and need to continue treatment but can't get it through regular prescriptions. T…

This study is observing patients in Russia to see if adding the drug ribociclib to standard hormone therapy is better at preventing breast cancer from coming back after initial treatment. It will follow over 2,700 patients with stage II or III breast cancer who have had surgery. …

This study aims to monitor the safety of fingolimod (Gilenya), a daily oral medication, in Taiwanese adults newly starting treatment for relapsing-remitting multiple sclerosis. Thirty-four participants will take the medication for one year while researchers track side effects and…

This program provides access to the drug ruxolitinib for patients with serious conditions like certain blood cancers and severe graft-versus-host disease. It is for people who have no other treatment options and cannot join a standard clinical trial. The program allows doctors to…

This study is testing if a new oral medication called remibrutinib works faster than an existing injectable drug, dupilumab, to control chronic hives. It will involve about 400 US adults whose hives and itching are not controlled by standard allergy pills. Participants will take …

This early-stage study is testing a new drug called GVV858, both by itself and combined with standard hormone therapies, for people with advanced breast cancer and other solid tumors. The main goals are to find a safe dose and see how well the body handles the drug. Researchers w…

This study observes how well the medication ofatumumab controls multiple sclerosis in real-world medical settings in Greece. It follows 160 adults with relapsing MS who started ofatumumab within the last 5 years of their diagnosis. Researchers will track disease activity, disabil…

This study is testing a new, one-time treatment called rapcabtagene autoleucel for people with severe, hard-to-treat diffuse cutaneous systemic sclerosis (a severe form of scleroderma). It compares this CAR-T cell therapy, which involves modifying a patient's own immune cells, ag…

This study continues testing an experimental drug called pelacarsen for people with high levels of a specific blood fat (Lp(a)) and established heart disease. It's open only to people who successfully completed earlier trials of this medication. The main goal is to monitor the dr…

This study is testing a single infusion of a genetically modified cell therapy called rapcabtagene autoleucel for adults with severe lupus or lupus kidney disease that hasn't responded to at least two standard treatments. The goal is to see if this one-time treatment can put the …

This study is testing a new drug called ECI830 for people with advanced breast cancer that has stopped responding to standard hormone therapies. Researchers want to see if ECI830 is safe and effective when given alone or combined with two existing cancer drugs. The trial will enr…

This program provides access to the medication eltrombopag for patients with medically significant thrombocytopenia (low platelet count). Eligible patients include those with chronic immune thrombocytopenia (ITP), severe aplastic anemia, or hepatitis C who need interferon therapy…

This program provides access to the drug asciminib (ABL001) for patients with chronic myeloid leukemia who have run out of standard treatment options. It's designed for people who cannot join regular clinical trials and have no satisfactory alternative therapies available. The pr…

This study is testing whether an oral medication called remibrutinib can safely reduce painful skin lesions in people with moderate to severe hidradenitis suppurativa (HS). About 555 participants aged 12 and older will take either one of two doses of the drug or a placebo pill fo…

This study is testing whether a new drug called LXE408 can clear or reduce the parasite that causes chronic Chagas disease. The trial will involve 130 adults with the disease but without severe organ damage. Researchers will compare LXE408 against a placebo and the current standa…

This early-stage trial is testing a new CAR-T cell therapy called rapcabtagene autoleucel for people with severe rheumatoid arthritis and Sjogren's disease that hasn't responded to standard treatments. The study will primarily check if the treatment is safe and how the modified c…

This is an early-stage study to check the safety and how the body processes a new drug called PIT565 for people with active lupus (SLE). It will involve about 54 participants who haven't responded well to standard treatments. The main goal is to find a safe dose and see how the d…

This study is testing whether adding an investigational oral drug called iptacopan to standard supportive care can reduce harmful immune activity and slow kidney damage in adults with IgA nephropathy. Researchers will compare kidney biopsies from 20 participants before and after …

This study is monitoring the safety and effectiveness of the drug eltrombopag in children with aplastic anemia who are starting a specific treatment for the first time. It will follow about 10 children, aged 6 to 18, for one year to track any side effects and see how well their b…

This program provides access to the breast cancer drug ribociclib for patients who have exhausted standard treatments or need it as additional therapy after surgery. It's designed for people with advanced cancer that has stopped responding to available options, or for early-stage…

This study is testing whether an experimental medication called GXV813 can safely reduce symptoms in adults hospitalized for an acute schizophrenia episode. Researchers will compare GXV813 against a placebo in 142 participants over 6 weeks, measuring changes in symptoms like hall…

This study follows 177 patients in Saudi Arabia who are already taking ribociclib plus hormone therapy for early-stage breast cancer. Researchers will observe how well the treatment works and what side effects occur in real-world medical practice over 3 years. The study doesn't c…

This large, late-stage study is testing whether a new drug called votoplam can slow down the progression of Huntington's disease in people who have just started showing symptoms. About 770 participants will receive either the drug or a placebo for up to three years to see if it h…

This study follows patients who previously participated in zigakibart trials to monitor long-term safety and effectiveness for IgA nephropathy, a chronic kidney disease. About 220 adults will receive the drug every two weeks for up to two years while researchers track side effect…

This study is testing whether an investigational drug called VHB937 can help slow the progression of early Alzheimer's disease. About 407 participants with mild memory problems or early Alzheimer's will receive either VHB937 or a placebo for 72 weeks, followed by an extension per…

This study is testing an inhaled drug called glycopyrronium to see if it helps children aged 6 to 12 with moderate to severe asthma breathe better. About 42 children will try two different doses of the drug and a placebo (an inactive substance) in a random order to compare their …

This early-stage study is testing a single dose of an experimental cell therapy called YTB323 in about 15 people with severe, treatment-resistant myasthenia gravis. The main goals are to see if the treatment is safe and to measure how it affects the body and the severity of muscl…

This study is testing whether a monthly injection called pelacarsen can slow down the worsening of a narrowed and hardened heart valve (aortic stenosis). It will involve about 502 adults aged 50-80 who have mild-to-moderate valve disease and a specific high blood marker. Particip…

This program provides a medicine called clofazimine to adults with serious Non-Tuberculous Mycobacterial (NTM) lung infections. It is for patients who have tried other treatments that didn't work, caused bad side effects, or aren't an option. The medicine is given through a speci…

This program provides access to a CAR-T cell therapy called tisagenlecleucel (Kymriah) for patients with acute lymphoblastic leukemia or diffuse large B-cell lymphoma when their personalized treatment product doesn't meet the usual manufacturing standards for commercial release. …

This study continues testing ianalumab, an investigational drug for moderate-to-severe lupus, to understand its long-term safety and side effects. It includes 550 patients who previously completed earlier phases of this research program. The goal is to see if the drug remains saf…

This is an early-stage study to test the safety and find the right dose of a new radioactive drug called [225Ac]Ac-ETN029 for adults with advanced cancers that have a protein called DLL3. The trial will also test an imaging version of the drug to see where it goes in the body. Re…

This study aims to see if a new combination asthma inhaler (QMF149) works better and is as safe as a commonly used inhaler (budesonide) for children aged 6 to 12. About 200 children with asthma will try each inhaler for 12 weeks in a random order. Researchers will measure lung fu…

This study is testing a new two-part treatment for advanced breast cancer that has spread and stopped responding to standard hormone therapies. It combines a radioactive drug designed to find and attack cancer cells with a common chemotherapy pill. The goal is to find the safest …

This program provides access to the investigational drug iptacopan for patients with two rare, serious conditions: C3 glomerulopathy (a kidney disease) and paroxysmal nocturnal hemoglobinuria (a blood disorder). It's for patients who have no other treatment options available and …

This study is testing an experimental drug called GIA632 for adults with non-segmental vitiligo, a condition that causes loss of skin color. Researchers want to find the most effective and safe dose to reduce white patches on the face and body. The trial involves 210 participants…

This study is testing whether adding a new drug called tulmimetostat to standard prostate cancer treatments can better control the disease in men whose cancer has spread. The first part determines safe doses, and the second part compares the new combination against standard treat…

This study is for people who have already been in a related trial for the drug iptacopan. It aims to see how safe and effective the drug is over many years for two rare and serious kidney diseases, C3G and IC-MPGN. The goal is to control the disease, protect kidney function, and …

This program provides access to the drug alpelisib for patients with PIK3CA-Related Overgrowth Spectrum (PROS), a rare genetic condition causing abnormal tissue growth. It's designed for patients with severe or life-threatening cases who have no other feasible treatment options. …

This is an early-stage study to check the safety and how the body processes a new oral drug called JSB462. It involves about 15 Japanese men whose prostate cancer has spread and who have few other treatment options. The main goal is to find a safe dose by closely monitoring patie…

This study observes how well the cholesterol-lowering medication Leqvio (inclisiran) works for patients in everyday Spanish medical practice. It follows 200 adults with high cholesterol due to inherited conditions or existing heart disease. Researchers will check if patients reac…

This study is testing a new drug called LTP001 for people with pulmonary arterial hypertension (PAH), a serious condition that affects blood flow from the heart to the lungs. The trial has two parts: first testing safety in healthy volunteers, then testing if the drug helps peopl…

This study is observing patients in Germany and Austria who are already taking a specific drug combination (ribociclib plus an aromatase inhibitor) to prevent their early-stage, hormone-sensitive breast cancer from coming back. It aims to see how well the treatment works, what si…

This study is testing if adding a new daily pill called JSB462 to a targeted radiation therapy (lutetium) works better than the radiation therapy alone for men with advanced prostate cancer that has stopped responding to standard hormone treatments. The goal is to see if this com…

This study is testing if switching adults with atypical hemolytic uremic syndrome (aHUS) from their current injected treatment to a new oral pill called iptacopan is safe and keeps the disease under control. It will enroll about 50 adults who are currently stable on their standar…

This study is testing the drug ruxolitinib in Chinese adults and adolescents (age 12+) who have developed a serious complication called acute graft-versus-host disease (GvHD) after a stem cell transplant, and whose condition has not improved with standard steroid treatment. The g…

This study is observing how well the drug secukinumab works for people in Korea with ankylosing spondylitis, a type of inflammatory back arthritis. It will follow 70 adults who have never tried certain advanced medications for their condition. Researchers will track changes in pa…

This study is testing whether adding a medication called ribociclib to standard hormone therapy helps prevent breast cancer from returning after surgery. The trial will enroll 1,400 adults with high-risk, early-stage breast cancer that is hormone-positive and HER2-negative. Parti…

This study is testing whether adding a targeted radiation drug to standard hormone therapy works better than hormone therapy alone for newly diagnosed advanced neuroendocrine tumors of the gut and pancreas. The trial will enroll 240 patients with high disease burden to see if the…

This study is testing if an oral medicine called EYU688 can help people with dengue fever get better faster. It will compare the drug to a placebo (a pill with no medicine) in 108 adults who have had a fever for less than two days. The main goals are to see if EYU688 lowers the a…

This study is testing a drug called inclisiran to see if it is safe and effective at lowering very high 'bad' cholesterol (LDL-C) in children aged 2 to under 12 who have a rare, severe genetic condition. For the first year, children will randomly receive either the drug or a plac…

This program provides access to the investigational drug remibrutinib for adults with severe chronic hives (CSU) that hasn't responded to standard treatments. It's for patients who cannot join a regular clinical trial. The goal is to help control this difficult skin condition whe…

This study is testing whether a second course of the drug ianalumab can safely help control two rare blood disorders—ITP and wAIHA—in adults who benefited from it before but later relapsed. It will enroll about 60 people who previously participated in related ianalumab trials. Th…

This study is testing whether the drug asciminib can help control chronic myeloid leukemia in patients with a specific genetic mutation called T315I. The trial focuses on people who have already tried other treatments and either didn't respond well or couldn't tolerate them. Rese…

This study is testing whether adding a new injectable drug called ianalumab to standard lupus nephritis treatment can better protect kidney function. About 462 adults with active lupus kidney disease will receive either ianalumab injections every 4 or 12 weeks or a placebo inject…

This early-stage study is testing a new radioactive drug treatment for people with advanced solid tumors that have stopped responding to standard therapies. Researchers will first use a special imaging scan to see if patients' tumors are likely to respond, then give the radioacti…

This study is testing a new type of treatment called rapcabtagene autoleucel, a CAR-T cell therapy, for adults with severe inflammatory muscle diseases that haven't responded to other treatments. It will compare this new therapy against a standard treatment option to see which is…

This study is testing whether a new combination of two drugs, tulmimetostat and JSB462, is safe and works better than current standard treatments for advanced prostate cancer that has spread and stopped responding to hormone therapy. The first part of the study will find the safe…

This study is testing how well a combination of two targeted drugs works for people with rare, advanced cancers that have a specific genetic change (BRAF V600E mutation). It is open to both adults and children (age 1+) who have not been treated with these specific drugs before. T…

This study aims to understand how well a targeted radioactive drug works for men with advanced prostate cancer that has spread, in real-world hospital settings across China. It will follow about 170 patients who are already scheduled to receive this treatment, observing their hea…

This study is testing whether adding a new experimental drug, JSB462, to standard hormone therapy works better and is safe for men whose prostate cancer has spread but still responds to hormone treatment. It will involve about 150 men and compare the new combination against curre…

This study is testing whether an investigational drug called pelacarsen can safely lower high levels of a blood fat called lipoprotein(a) (Lp(a)), which is linked to heart disease risk. It involves about 340 adults who already have heart disease and are taking another cholesterol…

This study is testing an experimental drug called AAA817 against standard treatments for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, chemotherapy, and a specific type of targeted radiation therapy. The goal is to see if AAA817 can …

This study is testing a drug called inclisiran to see if it safely lowers bad cholesterol in children aged 6 to 12 who have an inherited condition causing very high cholesterol. For the first year, some children will receive the drug and others a placebo, followed by a year where…

This study is for men whose prostate cancer has returned and spread to a few locations after initial treatment. It aims to see if a targeted radiation drug (lutetium vipivotide tetraxetan) can better control the cancer and delay the need for hormone therapy compared to just monit…

This study is observing how well a medication called asciminib works for adults in Saudi Arabia with a type of chronic leukemia. It is for patients who have already tried at least two other standard treatments. Researchers will follow about 40 patients for a year to see how effec…

This is the first study of a new drug called ITU512 for sickle cell disease. Researchers will first test its safety in healthy adults, then see if it can help patients by boosting a protective type of hemoglobin. The goal is to see if the drug can safely control the disease and r…

This study is testing whether an investigational drug called crizanlizumab can reduce the frequency of painful vaso-occlusive crises in people with sickle cell disease. It will involve about 315 adolescents and adults who experience frequent pain crises, comparing the drug agains…

This study is observing how well the drug iptacopan works and how safe it is for adults with paroxysmal nocturnal hemoglobinuria (PNH) in everyday Russian medical practice. It will follow 100 patients already prescribed the drug by their doctors to see if it increases their hemog…

This study is for people with relapsing multiple sclerosis (MS) who are currently getting ocrelizumab infusions. It will test if switching to a new pill called remibrutinib works as well to control the disease. About 360 participants, aged 40-70, will be randomly assigned to eith…

This is a special access program, not a traditional clinical trial. It provides the experimental drug ianalumab (VAY736) to patients with serious immune conditions like Primary Immune Thrombocytopenia (ITP) and Sjögren's Syndrome. The program is for patients who have no other tre…

This study is testing a new three-drug combination for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The trial has two parts: first to find a safe dose, then to see if the combination can effectively shrink tumors and lower …

This study is monitoring the safety and effectiveness of Fabhalta capsules in 100 patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers will track patients for 48 weeks after starting treatment to watch for infections, side effects, and how w…

This study is observing how well the approved drugs dabrafenib and trametinib work and how safe they are for patients with advanced solid tumors that have a specific BRAF V600E mutation. It will follow about 110 adult and pediatric patients in real-world medical settings, trackin…

This early-stage study is testing a radioactive drug called AAA617 for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The main goals are to see where the radiation goes in the body, measure how much radiation organs and tumor…

This study aims to understand how well a targeted radiation drug works for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. Researchers will follow 300 patients in real-world clinics for up to 18 months after treatment to see h…

This study is testing whether an investigational oral drug called remibrutinib can better control the symptoms of chronic hives compared to a placebo. It will involve about 44 adults whose hives are not well-managed by standard antihistamine medications. Participants will take ei…

This study is testing whether a pill called alpelisib can shrink abnormal lymphatic growths and improve symptoms in children and adults who have these growths due to a specific genetic change. It will compare the drug to a placebo (a pill with no medicine) to see if it works bett…

This study is monitoring the safety and real-world effectiveness of an already-approved drug called Cosentyx (secukinumab) in Korean patients. It will follow 76 people with moderate-to-severe hidradenitis suppurativa (a painful skin condition), pediatric plaque psoriasis, or juve…

This program provides eligible sickle cell disease patients with access to an investigational drug called crizanlizumab. The goal is to help prevent or reduce the frequency of painful vaso-occlusive crises (VOCs) in patients aged 12 and older who continue to experience these cris…

This study aims to understand how a medication called secukinumab behaves in children's bodies and whether it's safe for long-term use. It will follow about 20 children aged 2 to 18 with juvenile psoriatic arthritis for up to six years. Researchers will give the medication throug…

This study follows 175 patients with spinal muscular atrophy (SMA) for five years after they received the gene therapy OAV101 in earlier trials. The main goal is to monitor the long-term safety of the treatment and see if its benefits in improving motor skills are sustained over …

This program provides access to the drug ceritinib for patients with ALK-positive cancers, including lung cancer and pediatric tumors, when no other treatments are available. It is for people who cannot join regular clinical trials and have serious or life-threatening conditions.…

This study aims to see how well the drug secukinumab works for people with moderate-to-severe hidradenitis suppurativa (HS) in real-world Canadian clinics. It will follow 142 adult patients newly prescribed this medication to track changes in their disease severity, side effects,…

This study aims to see how well the drug secukinumab works for adults with moderate to severe hidradenitis suppurativa (HS) in real-world medical settings. It will follow 300 patients in Russia who are already starting this treatment as part of their normal care. Researchers will…

This study is testing if starting a cholesterol-lowering injection called inclisiran soon after a heart attack helps prevent future heart-related events like another heart attack or stroke. It will follow 300 patients in Russia for one year to see if the drug, added to their usua…

This study is testing whether a new oral medication called PKN605 can safely reduce the amount of time people spend in atrial fibrillation (AF), a common irregular heartbeat. About 165 adults with a history of AF will take either PKN605 or a placebo pill daily for 24 weeks while …

This study aims to see how well a drug called remibrutinib works for people with chronic hives in real-world settings, outside of a controlled clinical trial. It will enroll 350 adults in the US who are starting this medication. Researchers will track how well the drug controls h…

This study is testing whether an experimental medication called GIA632 can help control moderate to severe eczema (atopic dermatitis). Researchers will compare GIA632 against a placebo in 84 adult participants over 16 weeks to see if it improves skin symptoms and is safe to use. …

This study is testing different doses of an investigational eye injection called FWY003 to see if it can slow the progression of geographic atrophy, a late-stage form of age-related macular degeneration that causes permanent vision loss. About 272 participants aged 50+ with this …

This study is testing if starting a cholesterol-lowering medication called inclisiran very early after a heart attack or severe chest pain (acute coronary syndrome) is safe and effective. About 300 hospitalized patients will receive either inclisiran or a placebo (dummy injection…

This study is observing how a drug called iptacopan affects adults in China with a rare blood disease called paroxysmal nocturnal hemoglobinuria (PNH). It will follow 80 patients who are starting this new treatment to see if it improves their blood counts, reduces symptoms, and c…

This study is testing whether a special education and support program helps people with high cholesterol and a high risk of heart disease reach their cholesterol goals. About 326 adults in Abu Dhabi who are already on standard cholesterol medication will either receive the educat…

This study aims to gather real-world information on how well a new medication called remibrutinib works and how safe it is for people with chronic spontaneous urticaria (CSU), a condition causing long-lasting hives. It will follow 505 US patients whose doctors have already decide…

This study continues to monitor patients who have already completed previous cancer treatment studies with dabrafenib and/or trametinib. It tracks 100 patients with various cancers including melanoma and lung cancer to understand the long-term safety of these medications. The goa…

This study aims to understand if a prostate cancer drug called lutetium vipivotide tetraxetan is safe for men whose kidneys don't work well. Researchers will measure how much radiation the drug delivers to organs and track side effects in 20 men with advanced prostate cancer who …

This early-phase study is testing whether a single dose of an experimental cell therapy called YTB323 is safe for people with progressive multiple sclerosis (MS) who haven't had recent relapses. The trial will enroll 28 participants who will receive the treatment and then be moni…

This study is testing whether a radioactive drug called AAA817, when given with standard hormone therapy, can better control advanced prostate cancer that has spread and stopped responding to standard treatments. The trial will compare this combination against other standard trea…

This study is testing a new drug called EDI048 to see if it can reduce diarrhea and other symptoms caused by Cryptosporidium infection. Healthy adult volunteers will be given the infection on purpose and then receive either the drug or a placebo. The goal is to see if the drug wo…

This study is testing whether a mobile app can help people with a specific type of breast cancer stay on their prescribed medication. It will compare 240 patients who use the app with those who don't, tracking who continues their treatment over a year. The app provides informatio…

This study is testing an experimental drug called MAS825 in adults and children with Still's disease, a rare inflammatory condition. The main goal is to see if MAS825 can effectively control disease activity and reduce the need for steroid medications. Researchers will also monit…

This early-stage study is testing the safety and how the body processes a new rheumatoid arthritis drug called PIT565. The trial will enroll 57 adults with rheumatoid arthritis who will receive injections of the experimental medication. Researchers will monitor for side effects a…

This program provides access to the medication secukinumab for people with severe hidradenitis suppurativa, a painful skin condition. It's designed for patients who have tried all other available treatments without success and cannot join regular clinical trials. The program allo…

This study tests a modified version of a cell therapy (tisagenlecleucel) for patients with aggressive blood cancers when their manufactured treatment doesn't meet standard release specifications. It involves 200 children and adults with relapsed leukemia or lymphoma who have no o…

This study is testing if adding a new injectable cholesterol drug (inclisiran) to standard care helps patients better control their 'bad' cholesterol (LDL-C) after a recent heart attack, stroke, or urgent heart procedure. It will involve about 520 patients in Latin America who ar…

This study allows sickle cell disease patients who benefited from crizanlizumab treatment in previous Novartis trials to continue receiving the medication. It's designed for patients who have completed earlier studies but don't yet have access to commercially available treatment.…

This study is testing several new medications for people with moderate to severe eczema (atopic dermatitis). Researchers will compare the experimental treatments against a placebo to see which works better at reducing skin inflammation and symptoms. The trial involves 224 partici…

This study is observing how well the approved prostate cancer drug Pluvicto works and what side effects patients experience in real-world medical practice in South Korea. It will follow about 278 adult men with advanced prostate cancer that has spread and stopped responding to ho…

This study allows patients with chronic myeloid leukemia who benefited from asciminib in previous Novartis trials to continue receiving the drug while researchers monitor long-term safety. The study tracks side effects and confirms ongoing benefit for up to 347 participants who c…

This study is testing whether a daily pill called alpelisib can safely shrink overgrowths and improve symptoms in children and adults with PROS, a rare genetic disorder that causes abnormal tissue growth. About 104 participants aged 2 and older will take the drug for up to 3 year…

This study is testing a new type of treatment called rapcabtagene autoleucel, a CAR-T cell therapy, for people with severe forms of two autoimmune diseases that cause blood vessel inflammation (GPA and MPA). It will compare this one-time cell therapy to standard treatments to see…

This program provides access to an experimental drug called atrasentan for people with IgA nephropathy, a serious kidney disease. It's designed for patients who have no other treatment options and cannot join regular clinical trials. Doctors can request the medication for eligibl…

This 2-year extension study follows patients with lupus nephritis, a serious kidney disease caused by lupus, who completed an earlier trial. It aims to see if patients who improved can safely stop taking the study drug (ianalumab) without their disease flaring up, and to continue…

This large, late-stage study is testing whether an investigational drug called remibrutinib can slow or stop the worsening of disability in people with secondary progressive multiple sclerosis (SPMS). About 1,275 participants will be randomly assigned to receive either the drug o…

This study is testing whether the drug iptacopan can help control a rare kidney disease called C3G. About 98 patients aged 12-60 will receive either the drug or a placebo for 6-12 months, along with their standard care. Researchers will check if the drug reduces protein in urine,…

This study aims to see how well a new drug called remibrutinib works for controlling chronic spontaneous urticaria (CSU), or long-lasting hives, in everyday medical practice. It will follow about 3,280 adults whose doctors have already decided to either increase their current all…

This study is testing an experimental drug called QCZ484, given as an injection under the skin every six months, to see if it can safely lower and control high blood pressure. It will involve about 380 adults with mild to moderate hypertension. Researchers will compare different …

This study is testing an investigational drug called ianalumab to see if it can help control the progression of diffuse cutaneous systemic sclerosis, a severe form of scleroderma that causes skin thickening and can damage internal organs. About 200 adults with active, early-stage…

This study is testing an oral drug called iptacopan in children and teenagers with a rare kidney disease called IgA nephropathy (IgAN). The main goal is to see if the drug safely reduces protein in the urine, which is a key sign of kidney damage. About 34 participants, aged 2 to …

This study aims to monitor the safety and effectiveness of the drug Ilaris (canakinumab) in real-world clinical settings. It will include children and adults with rare hereditary fever syndromes or a form of juvenile arthritis who are already receiving the drug as part of their s…

This study is testing an investigational drug called iptacopan to see if it can help control symptoms and improve daily life for adults with generalized myasthenia gravis (gMG). About 146 participants will take either iptacopan or a placebo pill for 6 months while continuing thei…

This study aims to understand the long-term safety of the drug iptacopan for adults with IgA nephropathy, a kidney disease. It is open to 540 people who have already finished one of two earlier Novartis trials for this drug. The main goal is to monitor side effects for up to 3 ye…

This study is a long-term safety registry for patients in South Korea who have received Kymriah (tisagenlecleucel), a type of CAR-T cell therapy, for certain B-cell blood cancers. It will follow 500 patients for 15 years to monitor for any long-term side effects, including the ri…

This study is testing an investigational drug called DII235 to see if it can safely lower high levels of lipoprotein(a), a fatty particle in the blood linked to heart disease. It will involve about 200 adults who have heart disease or type 2 diabetes and high lipoprotein(a) level…

This study is testing an oral medication called iptacopan in children and teenagers (ages 2 to 18) with a rare and serious blood disease called Paroxysmal Nocturnal Hemoglobinuria (PNH). The main goals are to see how the drug behaves in children's bodies and to check if it is saf…

This study is monitoring the safety and effectiveness of Fabhalta capsules in patients with C3 glomerulopathy, a rare kidney disease. It will follow about 50 patients in real-world clinical practice for up to a year. The main goal is to track infections and other side effects, wh…

This study follows patients with polymyalgia rheumatica (PMR) who previously took secukinumab and experienced a relapse. It aims to check the long-term safety of continuing this treatment for up to two years. The research will monitor side effects and how well patients tolerate t…

This early-stage study is testing a new radioactive drug called [177Lu]Lu-NNS309 in patients with advanced pancreatic, lung, breast, or colorectal cancers that have stopped responding to standard treatments. Researchers will first use a special imaging scan to see if patients' tu…

This is the first study to test a new drug called EDK060 in people. It aims to check if the drug is safe and how it moves through the body in 28 adults with Charcot-Marie-Tooth disease type 1A (CMT1A). Participants will receive either the drug or a placebo, and researchers will c…

This study aims to monitor the safety of the heart medication Entresto in children aged 1 to 18 with chronic heart failure. It will follow 33 children in Japan for up to one year after they start taking the drug in their regular doctor's care. The main goal is to check for side e…

This study is testing a medicine called asciminib in children and teenagers (ages 1 to 18) with a specific type of blood cancer called Philadelphia chromosome-positive chronic myeloid leukemia. The main goal is to find the right dose for kids and check its safety, especially for …

This study is testing a new radioactive drug called 177Lu-FAP-2286 for people with advanced solid tumors that have stopped responding to other treatments. The drug is designed to find and deliver radiation directly to tumors by targeting a specific protein common in many cancers.…

This study is testing whether an oral medication called remibrutinib can help control symptoms and improve daily life for adults with generalized myasthenia gravis (gMG), a chronic autoimmune disease that causes muscle weakness. About 180 participants who are already on stable st…

This program provides access to the drug alpelisib for adults with advanced hormone-positive, HER2-negative breast cancer that has a specific genetic mutation (PIK3CA) and has progressed after standard hormone therapy. It's designed for patients who meet specific health criteria …

This study aims to see if adding two questions about morning stiffness and back pain, along with pictures, to an existing screening questionnaire helps doctors identify psoriatic arthritis in adults with moderate-to-severe plaque psoriasis. About 500 participants in Canada will f…

This study aims to understand how a medication called secukinumab affects the daily lives and satisfaction of people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Researchers will follow 60 patients in the United Arab Emirates for 24 weeks, coll…

This study surveys adults in Saudi Arabia with moderate to severe hidradenitis suppurativa (HS), a painful skin condition, who are starting a new treatment called secukinumab. Researchers will ask patients about their treatment satisfaction, pain levels, and quality of life over …

This study is testing a new eye-tracking tool to see if it can detect subtle changes in eye movements that might indicate how well a multiple sclerosis (MS) treatment is working. It will involve 224 Canadian adults with active relapsing-remitting MS who are already prescribed the…

This study aims to understand if a specific blood test, which measures a protein called neurofilament light, can help doctors predict disease activity in people with relapsing multiple sclerosis (MS). Researchers will observe 700 patients in Germany for up to two years as they ei…

This study aims to understand how well people with relapsing multiple sclerosis (MS) in Germany stay on their prescribed injectable or oral treatments in real-world settings. It will follow about 800 patients for up to four years, collecting data through questionnaires and medica…

This study aims to learn how well two newer breast cancer drugs, ribociclib and abemaciclib, work for people in everyday medical care, not just in controlled trials. It will follow 3,000 adults with a specific type of early-stage breast cancer to see how long they stay cancer-fre…

This study aims to measure how much of the multiple sclerosis (MS) medication ofatumumab passes into breast milk. It will enroll 20 breastfeeding mothers with relapsing MS who are starting or restarting this treatment after giving birth. Researchers will collect milk and blood sa…

This study aims to understand how lutetium treatment affects daily life and quality of life in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. Researchers will follow 500 patients receiving this approved treatment in real-world setting…

This study follows 1,400 patients for 15 years after they received CAR T-cell therapy for cancer. The goal is to monitor for any delayed side effects and track how well the treatment continues to work over time. Researchers want to understand the long-term safety profile of this …

This is the first study in humans to test the safety of a new drug called OJR520, which is being developed for chronic kidney disease. Researchers will give single and multiple doses to 112 healthy volunteers and people with kidney disease to see how their bodies handle the drug …

This study is monitoring the safety and real-world effectiveness of Leqvio, an injectable cholesterol-lowering medication, after its approval in Korea. It will follow 1,500 adult patients with high cholesterol who are already prescribed the drug by their doctors. The main goal is…